Breast Cancer | Specialty

The OncLive Breast Cancer condition center page is a comprehensive resource for clinical news and expert insights on various types of breast cancer, including those that are triple negative, hormone receptor positive, and/or HER2 positive. This page features news articles, interviews in written and video format, and podcasts that focus on treatment advances and ongoing research in breast cancer.

IMpassion130 Trial Data on PD-L1+ Tumors in TNBC

April 22nd 2020

Sequencing of Therapy in R/R HER2+ mBC

April 22nd 2020

SOPHIA Trial in R/R HER2+ mBC

April 22nd 2020

HER2CLIMB and NALA Trials: R/R HER2+ mBC

April 22nd 2020

Evolving Treatment Landscape of R/R HER2+ mBC

April 22nd 2020

Payer Coverage of IV Versus Oral Therapy in mBC

April 22nd 2020

Compliance and Adherence to Therapy in mBC

April 22nd 2020

Advantages of Oral Taxanes in mBC

April 22nd 2020

Payer Coverage on Repeat Biopsy in mBC

April 22nd 2020

Payer Perspective of Coverage on Cancer Therapies

April 22nd 2020

SOLAR-1 Trial in Metastatic Breast Cancer

April 22nd 2020

Treatment After Progression on CDK 4/6i in mBC

April 22nd 2020

Expert Highlights Benefit of PARP Inhibitors in BRCA+ Breast Cancer and Potentially Beyond

April 18th 2020

Melinda L. Telli, MD, discusses the role of PARP inhibition in the treatment of patients with breast cancer who harbor the BRCA mutations and ongoing research efforts seeking to expand their use beyond this setting.

Dr. Graff on Genomic Risk Prediction in HR+/HER2- Breast Cancer

April 11th 2020

Stephanie L. Graff, MD, discusses genomic risk prediction in patients with hormone receptor–positive, HER2-negative breast cancer.

A National Perspective on the Multidisciplinary Management of Breast Cancer Through the COVID-19 Pandemic

April 10th 2020

This OncLive® webinar will focus on the impact of COVID-19 in patients with breast cancer and the innovative ways in which treatment has evolved during this time. Join us on May 7, 2020 at 8 PM EDT.

Dr. Tolaney on Sequencing Questions in Breast Cancer

April 7th 2020

Sara M. Tolaney, MD, MPH, discusses remaining sequencing questions in breast cancer.

Evidence-Based Strategies Help Guide Need for ALND in Breast Cancer

April 5th 2020

Anees B. Chagpar, MD, outlines several strategies to minimize the use of ALND in patients with breast cancer.

Inclusion of Geriatric Populations in Breast Cancer Research Needed to Improve Care

April 3rd 2020

Enrique Soto Pérez de Celis, MD, MSc, discusses some of the challenges of treating geriatric patients with breast cancer, emerging treatment options for this patient population, and recommendations for treating older patients.

Dr. Kalinksy on pCR as a Surrogate Marker for EFS in TNBC

April 3rd 2020

Kevin Kalinsky, MD, MS, assistant professor of medicine, Division of Hematology and Oncology, NewYork-Presbyterian Hospital/Columbia University Medical Center, discusses the use of pathologic complete response (pCR) rate as a surrogate marker for event-free survival (EFS) in triple-negative breast cancer (TNBC).

Dr. Lynce on Remaining Questions With PARP Inhibitors in Breast Cancer

April 2nd 2020

Filipa Lynce, MD, discusses remaining questions regarding the use of PARP inhibitors in breast cancer.